<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2020-7-4-83-90</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-580</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДОЛОГИЧЕСКАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>METHODICS</subject></subj-group></article-categories><title-group><article-title>Методические аспекты профилактики контраст-индуцированного острого повреждения почек при ангиографических исследованиях и вмешательствах с использованием рентгеноконтрастных препаратов</article-title><trans-title-group xml:lang="en"><trans-title>Methodological aspects of the prevention of contrast-induced acute kidney damage during angiographic studies and interventions using radiocontrast agents</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лаврищева</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lavrishcheva</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаврищева Юлия Владимировна - врач-нефролог.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Lavrishcheva Iuliia V. – Nephrologist.</p><p>3 Kirov Military Medical Academy, Saint Petersburg</p></bio><email xlink:type="simple">lavrischeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Конради Александра Олеговна - доктор медицинских наук, профессор, чл.-корр. РАН, заместитель генерального директора по научной работе, заведующий НИО артериальной гипертензии Института сердца и сосудов.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Konradi Alexandra O. - MD, PhD, Professor, the Deputy Director on Science, Head of the Research Institute.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Jakovenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яковенко Александр Александрович - кандидат медицинских наук, доцент кафедры нефрологии и диализа.</p><p>Санкт-Петербург</p><p> </p></bio><bio xml:lang="en"><p>Yakovenko Aleksandr A. - MD, PhD, Associate Professor, Department of Nephrology and Dialysis.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захаров</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakharov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Захаров Михаил Владимирович - кандидат медицинских наук, доцент, полковник медицинской службы, заместитель начальника кафедры нефрологии и эфферентной терапии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Zakharov Michail V. - MD. PhD, Associate Professor, Department of Nephrology and Efferent Therapy.</p><p>SaintPetersburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное военное образовательное учреждение высшего образования «Военно-медицинская академия имени С. М. Кирова» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kirov Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2020</year></pub-date><volume>7</volume><issue>4</issue><fpage>83</fpage><lpage>90</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лаврищева Ю.В., Конради А.О., Яковенко А.А., Захаров М.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Лаврищева Ю.В., Конради А.О., Яковенко А.А., Захаров М.В.</copyright-holder><copyright-holder xml:lang="en">Lavrishcheva Y.V., Konradi A.O., Jakovenko A.A., Zakharov M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/580">https://transmed.almazovcentre.ru/jour/article/view/580</self-uri><abstract><p>Процедуры с использованием йодсодержащих рентгеноконтрастных веществ представляют риск для функции почек, особенно у пациентов с уже имеющейся почечной дисфункцией. Контраст-индуцирован-ная нефропатия является третьей по частоте причиной острого повреждения почек, а в группах высокого риска частота контраст-индуцированных нефропатий может приближаться к 20-30 %. Поэтому оценка и снижение риска контраст-индуцированной нефропатии остается очень важной проблемой. В мире не существует лечения контраст-индуцированной нефропатии, поэтому основное внимание уделяется ее профилактике. В данной методической статье подробно описывается определение, методология оценки рисков развития и постановки диагноза контраст-индуцированного острого повреждения почек. Также рассматриваются основные аспекты профилактики контраст-индуцированного острого повреждения почек при ангиографических исследованиях и вмешательствах с использованием рентгеноконтрастных препаратов. Особое внимание уделено гидратации как основному методу гидратации контраст-индуци-рованного острого повреждения почек с учетом соматического статуса пациента.</p></abstract><trans-abstract xml:lang="en"><p>Procedures using iodine-containing X-ray contrast agents pose a risk to kidney function, especially in patients with pre-existing renal dysfunction. Contrast-induced nephropathy is the third most common cause of acute kidney injury, and in high-risk groups the incidence of contrast-induced nephropathy may approach 20-30 %. Therefore, assessing and reducing the risk of contrast-induced nephropathy remains a very important issue. There is no treatment for contrast-induced nephropathy in the world, so the main focus is on its prevention. This methodological article describes in detail the definition, methodology for assessing the risks of development and diagnosis of contrast-induced acute kidney injury. The main aspects of prevention of contrast-induced acute kidney injury during angiographic studies and interventions using X-ray contrast agents are also considered. Particular attention is paid to hydration, as the main method of hydration of contrast-induced acute kidney injury, taking into account the somatic status of the patient.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диагностика</kwd><kwd>йодсодержащие рентгеноконтрастные вещества</kwd><kwd>контраст-индуциро-ванное острое повреждение почек</kwd><kwd>острое повреждение почек</kwd><kwd>профилактика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute kidney injury</kwd><kwd>contrast-induced acute kidney injury</kwd><kwd>diagnosis</kwd><kwd>iodine-based contrast agents</kwd><kwd>prevention</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kog MM, Aslan N, Kao AP, et al. Evaluation of X-ray tomography contrast agents: a review of production, protocols, and biological applications. Microsc Res Tech. 2019; 82(6): 812-848.</mixed-citation><mixed-citation xml:lang="en">Kog MM, Aslan N, Kao AP, et al. Evaluation of X-ray tomography contrast agents: a review of production, protocols, and biological applications. Microsc Res Tech. 2019; 82(6): 812-848.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zuo T, Jiang L, Mao S, et al. Hyperuricemia and contrast-induced acute kidney injury: a systematic review and meta-analysis. Int J Cardiol. 2016; 224: 286-294.</mixed-citation><mixed-citation xml:lang="en">Zuo T, Jiang L, Mao S, et al. Hyperuricemia and contrast-induced acute kidney injury: a systematic review and meta-analysis. Int J Cardiol. 2016; 224: 286-294.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ozrazgat-Baslanti T, Thottakkara P, Huber M, et al. Acute and chronic kidney disease and cardiovascular mortality after major surgery. Ann Surg. 2016; 264 (6): 987-996.</mixed-citation><mixed-citation xml:lang="en">Ozrazgat-Baslanti T, Thottakkara P, Huber M, et al. Acute and chronic kidney disease and cardiovascular mortality after major surgery. Ann Surg. 2016; 264 (6): 987-996.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. 2016; 30 (2): 215-228.</mixed-citation><mixed-citation xml:lang="en">Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. 2016; 30 (2): 215-228.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements. 2012; 2 (1): 1-126.</mixed-citation><mixed-citation xml:lang="en">KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements. 2012; 2 (1): 1-126.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28 (7): 2845-2855.</mixed-citation><mixed-citation xml:lang="en">van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28 (7): 2845-2855.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291 (19): 2328-2334.</mixed-citation><mixed-citation xml:lang="en">Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291 (19): 2328-2334.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4 (10): 1584-1592.</mixed-citation><mixed-citation xml:lang="en">Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4 (10): 1584-1592.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Z, Fu Q, Cao L, et al. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013; 8 (1): e55124.</mixed-citation><mixed-citation xml:lang="en">Sun Z, Fu Q, Cao L, et al. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013; 8 (1): e55124.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zagler A, Azadpour M, Mercado C, et al. N-acetylcysteine and contrast-induced nephropathy: a metaanalysis of 13 randomized trials. Am Heart J. 2006; 151(1): 140-145.</mixed-citation><mixed-citation xml:lang="en">Zagler A, Azadpour M, Mercado C, et al. N-acetylcysteine and contrast-induced nephropathy: a metaanalysis of 13 randomized trials. Am Heart J. 2006; 151(1): 140-145.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008; 248 (3): 807-816.</mixed-citation><mixed-citation xml:lang="en">Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008; 248 (3): 807-816.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and metaanalysis. Ann Intern Med. 2016; 164 (6): 406-416.</mixed-citation><mixed-citation xml:lang="en">Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and metaanalysis. Ann Intern Med. 2016; 164 (6): 406-416.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Barbieri L, Verdoia M, Suryapranata H, et al. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention. Int J Cardiol. 2019; 275: 48-52.</mixed-citation><mixed-citation xml:lang="en">Barbieri L, Verdoia M, Suryapranata H, et al. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention. Int J Cardiol. 2019; 275: 48-52.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2856-2869.</mixed-citation><mixed-citation xml:lang="en">van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2856-2869.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Krestan C. Contrast media — Guidelines for practical use. Radiologe. 2019; 59(5): 444-453.</mixed-citation><mixed-citation xml:lang="en">Krestan C. Contrast media — Guidelines for practical use. Radiologe. 2019; 59(5): 444-453.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
